Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.

Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH.

Chemotherapy. 2012;58(4):321-9. doi: 10.1159/000343165. Epub 2012 Nov 12.

2.

Increasing diversity in pediatric hematology/oncology.

Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM.

Pediatr Blood Cancer. 2011 Jul 15;57(1):147-52. doi: 10.1002/pbc.22977. Epub 2011 Jan 31.

3.

Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.

Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P.

J Clin Pharmacol. 2011 Aug;51(8):1205-12. doi: 10.1177/0091270010381499. Epub 2010 Oct 26.

PMID:
20978276
4.

Role of exercise and nutrition in menopause.

Hagey AR, Warren MP.

Clin Obstet Gynecol. 2008 Sep;51(3):627-41. doi: 10.1097/GRF.0b013e318180ba84. Review.

PMID:
18677156
5.

A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.

Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB.

J Thorac Oncol. 2008 Jun;3(6):631-6. doi: 10.1097/JTO.0b013e318174e01f.

6.

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2008 Feb 15;14(4):1111-5. doi: 10.1158/1078-0432.CCR-07-4097.

7.

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2006 Aug 15;12(16):4882-7.

8.

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML.

Clin Cancer Res. 2006 May 1;12(9):2834-40.

9.

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.

Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ.

Clin Cancer Res. 2005 Sep 15;11(18):6615-24.

10.

The genetics, diagnosis and treatment of amenorrhea.

Warren MP, Hagey AR.

Minerva Ginecol. 2004 Oct;56(5):437-55. Review.

PMID:
15531861
11.

Implementation of a smoking policy in the United States Army.

Hagey A.

N Y State J Med. 1989 Jan;89(1):42-4. No abstract available.

PMID:
2922137
12.

Multiphasic screening in a military community.

Hawryluk O, Hagey A.

Mil Med. 1980 Aug;145(8):539-41. No abstract available.

PMID:
6774288
13.

An occupational health "table of contents".

Hagey A.

Occup Health Nurs. 1978 Nov;26(11):19-21. No abstract available.

PMID:
250691

Supplemental Content

Support Center